Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma

Stephen M. Ansell

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma'. Together they form a unique fingerprint.